The global submucosal injections market is worth USD 1.3 Billion as of now and is expected to reach USD 2.3 Billion by the year 2033 at a CAGR of 5.8% between 2023 and 2033.
Submucosal injections are being increasingly administered in surgical centers and hospitals in diverse procedures. This factor is expected to take the submucosal injections market by storm in the forecast period.
The common submucosal agents include dextrose water, normal saline, hydroxypropyl methylcellulose, hydroxyethyl starch, hyaluronic acid, and Orise gel. They are used for treating diseases like polyps in the colon, cancers (esophageal, gastric, and small intestine), and Barrett’s esophagus. The basic objective is that of minimizing polypectomy. Also, there is an increase in the number of patients looking for treatment of premature or stomach cancer. Eleview is one of the submucosal lifting agents used for treating this kind of cancer. With minimally invasive procedures being on the anvil, the submucosal injections market is expected to grow on an unstoppable note in the forecast period.
Future Market Insights has entailed these facets with future perspectives in its latest market study entitled ‘Submucosal Injections Market’. It has its team of analysts and consultants to look through a 360-degree approach across macros and micros.
“With rising pool of patients suffering from endoscopic submucosal dissection systems, the global submucosal injections market is expected to grow on an astonishing note in the forecast period”, says an analyst from Future Market Insights.
Key Takeaways from Submucosal Injections Market:
- North America holds the largest market share with the US housing maximum cancer patients. This is evident from the fact that as per the USA National Cancer Institute, the rate of incidence of cancer is 442.4/1000K people per year.
- Europe holds the second-largest market share with the Netherlands and United Kingdom witnessing growing occurrences of esophageal cancer.
- The Asia-Pacific is expected to witness maximum turbulence in the submucosal injections market going forward. This could be credited to growing awareness regarding the importance of submucosal injections.
Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!
Competitive Submucosal Injections:
- The key players in submucosal injections market include Bio Space Inc., GI Supply Cosmo Pharmaceuticals N.V., Fujifilm Medical Systems, Medtronics Plc, Zeon Medical, Boston Scientific, Aries Pharmaceuticals, Sumitomo Bakelite Co., ERBE Elektromedizin GmbH, Ovesco Endoscopy AG, Olympus Corporation, Pharmascience Inc., Fujifilm Medical Systems, Inc., and likewise.
- The players mentioned above are into various modes of expansion like new product launches, mergers, acquisitions, partnerships, joint ventures, and likewise to strengthen its position in the submucosal injections market.
- Olympus, in September 2022, did announce USA distribution of EndoClot Submucosal Injection Solution and EndoClot Polysaccharide Hemostatic Spray.
What does the Report say?
- The research study is based on type of agent (Eleview and ORISE gel, normal saline, dextrose water, hydroxyethyl starch, hydroxypropyl methylcellulose, succinylated gelatin, hyaluronic acid, and fibrinogen mixture), by application (colorectal cancer, gastric cancer, esophageal cancer), and by end-user (surgical centers, hospitals, and others).
- With growing incidences of cancer all over, the global submucosal injections market is expected to grow on an impertinent note in the forecast period.
Key Manufacturers and Suppliers of Submucosal injections:
- Bio Space Inc.
- GI Supply Cosmo Pharmaceuticals N.V.
- FUJIFILM Medical Systems
- Medtronic Plc.
- Zeon Medical
- Boston Scientific
- Aries Pharmaceuticals
- Sumitomo Bakelite Co.
- ERBE Elektromedizin GmbH
- Ovesco Endoscopy AG
- Ovesco Endoscopy AG
- Olympus Corporation
- Pharmascience Inc.
- FUJIFILM Medical Systems, Inc.
Key Segments:
By Type of Agent:
- Eleview and ORISE gel®
- Normal saline
- Dextrose water
- Hydroxyethyl starch
- Hydroxypropyl methylcellulose
- Succinylated gelatin
- Hyaluronic acid
- Fibrinogen mixture
By Application:
- Colorectal Cancer
- Gastric Cancer
- Esophageal Cancer
By End User:
- Hospitals
- Surgical Centers
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- China
- Japan
- South Korea
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
